A Study on the Anti-Proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Sep 2009
At a glance
- Drugs Pioglitazone (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- 18 Sep 2009 Planned end date changed from 1 Dec 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 18 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Sep 2008 New trial record.